Quarterly report [Sections 13 or 15(d)]

License Agreements (Details)

v3.26.1
License Agreements (Details) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended
Jul. 31, 2026
Jun. 30, 2026
Dec. 31, 2012
Apr. 21, 2026
PRIDCor Therapeutics, LLC License Agreement        
License Agreements        
Percentage of Series A financing receivable       10.00%
Percentage of financing receivable except Series A financing       9.00%
Revenue remaining performance obligation   $ 0    
Revenue under the PRIDCor license agreement   0    
PRIDCor Therapeutics, LLC License Agreement | Subsequent event        
License Agreements        
Revenue under the PRIDCor license agreement $ 100,000      
PRIDCor Therapeutics, LLC License Agreement | Maximum        
License Agreements        
Percentage of royalty on net sales       15.00%
Amount of exit consideration       $ 100,000,000
Agreement        
License Agreements        
Percentage of non-voting membership interest     10.00%  
License agreement expiration period     25 years  
Serpin License Agreement | License for SP16 Development        
License Agreements        
Direct transaction costs   120,722    
Total consideration paid   12,030,389    
Serpin License Agreement | License for SP16 Development | Common Stock        
License Agreements        
Total consideration paid   2,108,828    
Serpin License Agreement | License for SP16 Development | Series A-2 Non-Voting Convertible Preferred Stock        
License Agreements        
Total consideration paid   $ 9,800,839